[ @entity136 plus XXXX versus @entity1206 plus @entity900 in the treatment of advanced @entity1149 ].

@entity1 @entity137 @entity882 @entity900 @entity1149 @entity1206 @entity1431 @entity136
BACKGROUND: To evaluate and compare the efficacy and @entity137 between combination of @entity136 and @entity900 (GC) and combination of @entity1206 and @entity900 (VC) in the treatment of @entity1 with advanced @entity1149 ( @entity1149 ). METHODS: Sixty-seven @entity1 with locally advanced or metastatic @entity1149 were enrolled into the study, with 32 @entity1 in GC group and 35 in VC group. @entity1 ' characteristics were similar between the two groups. They were given gemcitabine 1 000-1 250 mg/m  , or @entity1206 25 mg/m   on days 1 and 8, and @entity900 80-100 mg/m   on days 1-3. The chemotherapy was repeated every 3 weeks as a cycle. RESULTS: An objective response rate of 37.5% was observed in GC arm versus 34.3% in VC arm (P=0.59). The 1-year survival rate was 38.7% in GC compared to 34.3% in VC (P=0.48). The median survival duration was 9.5 months for GC arm and 8.6 months for VC arm. Myelosuppression was the major dose-limiting @entity137 . The incidence of @entity1431 was significantly higher in the VC group than that in DC group (P=0.01), while grade III/IV @entity882 occurred more frequently in the GC group than that in VC group (P=0.015). CONCLUSIONS: The GC combination is as equally active and well tolerated as the VC combination in the treatment of @entity1 with advanced @entity1149 .
